Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months in this group. Daniel Pollyea, MD, MS, shares results from this phase 1 study.
Recent Articles
Amino Acids Could Reduce Cancer Treatment–Related Diarrhea
Treatment-related diarrhea is a common adverse event (AE) associated with cancer-directed therapies, negatively affecting patients’ quality of life (QOL) and leading to treatment delays...
Study Highlights Barriers to Greater AP Understanding of Immuno-oncology
According to results from a survey of U.S. oncology advanced practitioners (APs), APs express growing familiarity with immuno-oncology (IO) therapies, though issues such as...
Does Rehabilitation Improve Physical Well-Being and Quality of Life for Cancer Survivors?
Individualized rehabilitative instruction may lead to improvements in quality of life and significant physical benefits for cancer survivors, according to findings presented at JADPRO...
A New Clinical Ladder for Advanced Practitioners Improves Retention, Engagement
Five years after implementing a “clinical ladder” for advanced practitioners (APs), Moffitt Cancer Center reports higher AP retention and recruitment rates, as well as...
AP-Led Team Reduces Procedural Time for Ultrasound-Guided Paracenteses and Thoracenteses
Implementing an advanced practitioner (AP)–led team to perform ultrasound-guided paracentesis and thoracentesis at the bedside decreased patient wait time and use of interventional radiology...
Current Issue
October 2021, Volume 7, Issue 12
This issue tells the long story of drug shortages, demystifies transfusion services, and more.